Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30400959 | 1.00 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGDTSHRSMN1; SMN2 | |
| SCHEMBL18602999 | 0.95 | ALDH1A1 (0.35) | ALDH1A1MAPTHPGDTSHRSMN1; SMN2 | |
| SCHEMBL12580715 | 0.90 | CYP1A2 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL28900411 | 0.87 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL17267078 | 0.85 | SHBG (0.30) | — | |
| SCHEMBL6014062 | 0.85 | SHBG (0.30) | — | |
| SCHEMBL7167521 | 0.84 | — | — | |
| SCHEMBL9405647 | 0.84 | MEN1 (0.31) | — | |
| SCHEMBL16314440 | 0.84 | MEN1 (0.31) | — | |
| SCHEMBL6254499 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759781-B2 | Substituted guanidine derivatives | UBE INDUSTRIES, LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 2019-05-23 | — | — | US | disclosed |
| EP-2044016-B1 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | GRUENENTHAL GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| EP-2044016-A2 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | Grünenthal GmbH (DE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008009415-A2 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1- AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
| EP-0624163-B1 | CYCLIC CALCITONIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION | SMITHKLINE BEECHAM FARMA (IT) | 1998-03-25 | — | — | EP | disclosed |
| EP-0624163-A1 | CYCLIC CALCITONIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1994-11-17 | — | — | EP | disclosed |
| WO-1993015106-A1 | CYCLIC CALCITONINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759781-B2 | Substituted guanidine derivatives | GMPS, GUCY1A1, GUCY1A2 | ALDH1A1 687/4885MAPT 2077/4885HPGD 1290/4885 |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | GMPS, GUCY1A1, GUCY1A2 | ALDH1A1 687/4885MAPT 2077/4885HPGD 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.